Navigation Links
DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
Date:4/9/2013

San Diego, CA (PRWEB) April 09, 2013

The drug safety advocates at DrugRisks.com are alerting of updated legal news on the site for patients who have taken the diabetes drug Actos. Trial continues against the maker of the drug for a man alleging it caused his terminal bladder cancer***.

DrugRisks is designed to improve the safety of those taking popular prescription drugs like Actos by providing the latest warnings, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice.

The FDA and European Medicines Agency* have warned that taking Actos for longer than one year may be associated with an increased risk of bladder cancer. Regulators in France and Germany have also banned it from being prescribed**.

The resource center discovered as many as 3,000 patients in the U.S. have filed an Actos lawsuit against Takeda Pharmaceuticals over allegations their drug caused bladder cancer***. The first trial began last month in California for Jack Cooper, a grandfather who is terminally ill from the disease***.

Now DrugRisks notes an article from Law360 on March 26, 2013 which quotes the testimony in this case of Dr. Norm D. Smith, an assistant professor of urology and surgery at the University of Chicago, that Actos was the “most substantial causative factor” of Mr. Cooper’s advanced cancer****.

Lawyers continue to help those diagnosed with bladder cancer after taking Actos file claims. Anyone affected is urged to contact the DrugRisks Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of drug injury litigation against large pharmaceutical companies, DrugRisks only recommends lawyers and law firms who have already handled Actos lawsuits.

Visit http://www.DrugRisks.com today for more information on Actos bladder cancer research, side effects and litigation news, or to speak with a lawyer.

*fda.gov/ForConsumers/ConsumerUpdates/ucm263431.htm#Actos; ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/hu an_pha_detail_000033.jsp&mid=WC0b01ac058001d126
**cbsnews.com/8301-504763_162-20070492-10391704.html
***bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html; Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court (Los Angeles).
****Claran McEvoy, "Actos 'Most Substantial" Factor in Man's Cancer, Doc Testifies," March 26, 2013, Law360

Read the full story at http://www.prweb.com/releases/actos-lawsuit-2013/bladder-cancer/prweb10610892.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
2. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
3. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
4. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
5. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
6. Johnson & Johnson Ethicon Transvaginal Mesh Lawsuits Update: Resource4thePeople Reports Judge Schedules More Trials for This Summer
7. DrugRisk Update: Mirena Maker Asks to Keep Lawsuits With Local Court, Judge
8. DrugRisk Update: Bayer Adds Gallbladder Claims to Yaz Settlements
9. Skechers Injury Lawsuit Update: Richard W. Schulte, Partner with Wright & Schulte LLC, Appointed to Plaintiffs’ Steering Committee in California Skechers Toning Shoes Litigation
10. DrugRisk Update: New Pradaxa Study Questions FDA Safety Conclusion
11. Hip Safety Center Update: Patients Ask to Send Stryker Hip Lawsuits to Federal Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by a ... diaphragmatic hernia have better survival rates if surgery is performed early. Approximately one ... the diaphragm fails to form completely, letting abdominal organs into the chest cavity ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... ... is the deadliest type of skin cancer. Although only about 1 percent of skin cancer ... than 10,000 people are expected to die of melanoma this year. The risk increases with ... the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may ...
(Date:4/29/2016)... , ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon ... is a very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to ... is a procedure that involves one or both jaw bones. This surgery is performed to ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  Marking its one ... breast and ovarian cancer risk test, Color ... 30 genes that highly impact the most common ... today, the Color Test analyzes hereditary cancer risks ... and uterine cancers. The Color Test is physician ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... Ste phen Schmidt Join the ... software solutions for life sciences, today announced key new leaders have ... insight to a growing business.  This will bolster the company,s safety ... joined ArisGlobal in the position of Vice President - Safety. ...
(Date:4/28/2016)... India , April 28, 2016 ... Pipeline Review, H1 2016" is a report that ... and helps strengthen R&D pipelines by identifying new ... products. Company Profiles discussed in this ... Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma ...
Breaking Medicine Technology: